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1. Introduction 
In all mammals, including humans, the immune system is responsible for the protection 
against potentially hazardous pathogens, such as bacteria, viruses, parasites and fungi. In 
this remarkably effective defense system leukocytes, which mediate both innate and 
adaptive immune responses, play a central role. 
The innate immune system comprises granulocytes (neutrophils, eosinophils and basophils), 
natural killer (NK) cells, mast cells and macrophages. These cells are the first line of defense 
and provide the immediate response against pathogens. Neutrophils and macrophages can 
eliminate a pathogen directly by phagocytosis. Moreover, their pattern-recognition 
receptors, recognizing structurally conserved molecules derived from microbes such as 
bacterial lipopolysaccharides, unmethylated CpG, or viral double-stranded RNA, allow 
them to respond to a wide variety of microbial invaders, e.g. by producing cytokines that 
activate T lymphocytes of the adaptive immune system.  
Acquired or adaptive immunity is characterized by a slower but highly specific immune 
response. Three major cell types are involved in adaptive immunity: antigen presenting cells 
(APCs), T lymphocytes and B lymphocytes. Dendritic cells (DCs) are the most potent APCs. 
They act as messengers between the innate and the adaptive immune system by taking up, 
processing and presenting antigens to T lymphocytes. In response to presented antigens, T 
lymphocytes may react in different ways: CD4+ T helper cells produce various cytokines 
that direct the immune response, whereas CD8+ cytotoxic T cells produce toxic granules that 
induce death of infected cells. B cells are able to respond to pathogens by terminal 
differentiation into plasma cells after which they produce large quantities of antibodies. 
Modulation of B cell function and antibody production by CD4+ T cells is an important step 
in coordinating immune responses. Upon activation, B cells can migrate to germinal centers, 
which are specialized structures in secondary lymphoid organs, where they interact with T 
cells and DCs. Costimulatory signals from T cells then facilitate selection of B cells with high 
affinity for immunoglobulins and control class switching of the immunoglobulin (Ig) to IgG, 
IgA and IgE. 
Following pathogen elimination, lymphocytes leave a lasting legacy of the antigens they 
have come across represented by memory cells. As a result, lymphocytes are able to mount a 
faster and stronger immune response in future encounters with the same antigen. Defective 
T cell function can increase susceptibility to infections, allergies and autoimmune diseases. T 
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lymphocytes can however also be manipulated to either eradicate tumor or control graft 
rejection after organ transplantation. Therefore, in addition to basic biological interest, 
knowledge on T cell biology is important to the understanding of the etiology of a wide 
variety of diseases and may improve current therapies.  
During activation in a particular cytokine milieu, naïve CD4+ T cells can differentiate into 
one of the several subsets of T helper (Th) cells. Already in 1986, Mosmann and Coffman 
introduced the concept of distinct types of T helper cells, which was based on the distinct 
cytokines profiles that T cells produce when they are stimulated to differentiate (Mosmann 
and Coffman 1989).  They described two types of Th lymphocytes, type 1 helper T cells (Th1 
cells) and type 2 helper T cells (Th2 cells). Th1 cells produce large quantities of interferon 
(IFN)Ǆ, induce delayed hypersensitivity reactions, activate macrophages, and are essential 
for the defense against intracellular pathogens. Th2 cells produce mainly interleukin (IL)-4 
and are important in inducing IgE production, recruiting eosinophils to sites of 
inflammation, and helping to clear parasitic infections. Cytokines produced by cells of the 
innate immune system govern the differentiation of these T helper cells. IFNǄ and IL-12 
drive naive T cells into the Th1 pathway, whereas IL-4 initiates the differentiation of naive T 
cells into Th2 cells. At a molecular level, the differentiation of Th1 and Th2 cells requires 
specific transcription factors: T-bet for Th1 cells (Szabo et al. 2000) and GATA3 for Th2 cells 
(Zheng and Flavell 1997) (Figure 1). An additional T helper subset was recently identified 
which restrains excessive effector T cell responses and therefore accounts for the 
maintenance of immune homeostasis and prevention of immunopathology. These cells are 
called regulatory T (Treg) cells and are naturally present in the immune system as a 
functionally distinct CD4+ T cell expressing the forkhead transcription factor FoxP3 and 
producing the cytokines IL-10 and transforming growth factor (TGF)-ǃ. The differentiation 
of naïve T cells towards this lineage is driven by IL-2 and TGF-ǃ (Weaver and Hatton 2009) 
(Figure 1). T follicular helper (Tfh) cells are yet another CD4+ T cell population (Nurieva et 
al. 2008; Vogelzang et al. 2008). They are important for the formation of germinal centers. 
Once these germinal centers are formed, Tfh cells are needed to maintain and regulate B cell 
differentiation into plasma cells and memory B cells. The signals that specifically instruct the 
differentiation of human Tfh cells remain unclear, but IL-12 and IL-21 seem to be required. 
Tfh cells express Bcl6 as their master transcription factor and may produce IL-21 and IL-4 
(Yusuf et al. 2010; Ma et al. 2009; Crotty 2011) (Figure 1).  
Interestingly, in recent years T cells were shown to produce proinflammatory cytokines that 
could not be classified according to this Th1-Th2 scheme. IL-17 is the most prominent 
amongst these cytokines, and T cells that preferentially produce IL-17 but not IFNǄ or IL-4 
were named Th17 cells. The discovery of this new subset of helper T cells that selectively 
produces IL-17 has provided better and exciting insights into immunoregulation, host 
defense and the pathogenesis of autoimmune diseases. In particular, it now appears that 
Th17 cells do not only play a key role in chronic inflammatory lung disorders, but also 
mediate protective immunity against various pathogens at respiratory mucosal sites.  
2. Interleukin 17 and T helper 17 cells 
IL-17 (also denoted IL-17A) was cloned in 1993 and initially called CTLA-8 (Rouvier et al. 
1993). In 1995, it was renamed as IL-17, its receptor was cloned and it was identified as a 
cytokine expressed by T cells, exerting effects on epithelial, endothelial, and fibroblast cells 
(Yao et al. 1995). IL-17 has diverse biological functions, but the best characterized functions  
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Fig. 1. Overview of human CD4+ effector T cell differentiation. 
Upon activation in a particular cytokine milieu, naïve CD4+ T cells may differentiate into one 
of several lineages of T helper (Th) cells, including Th1, Th2, Th17, and Treg cells. These 
separate lineages are characterized by their distinct cytokine production pattern. The 
differentiation pathways are mainly based on the induction of transcription factors that 
serve as master regulators of specific lineages. However, cytokine production by Th cells 
seems to be more flexible than previously believed and recently new cells, such as Th22 and 
Tfh cells have been described. Whether these new subsets represent distinct lineages 
remains to be elucidated. 
relate to its proinflammatory effects. Specifically, IL-17 recruits neutrophils via effects on 
granulopoiesis (Schwarzenberger et al. 1998; Fossiez et al. 1996) and CXC chemokine 
induction, including CXCL8/IL-8 (Laan et al. 1999). Furthermore, it acts on macrophages to 
promote their recruitment and survival and stimulates the production of proinflammatory 
cytokines and anti-microbial peptides, particularly ǃ-defensins, from a variety of immune 
and non-immune cells (Kolls and Linden 2004; Weaver et al. 2007; Ouyang, Kolls, and 
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Zheng 2008; Crome, Wang, and Levings 2010). By now we know that the IL-17 family 
includes 6 family members: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17A and 
IL-17F are the most closely related isoforms, sharing 55% homology with each other. 
Because of their structural and functional similarities and the fact that they are both 
produced by Th17 cells, IL-17A and IL-17F have been most thoroughly studied and 
characterized. Although it was known for more than 15 years that IL-17 is a product of 
activated CD4+ T cells, it was not until 2005 that the Th17 cell was described as a distinct 
CD4+ T-cell subset, critically responsible for the production of IL-17 in the context of 
autoimmunity (Harrington et al. 2005). 
2.1 Phenotype and differentiation of Th17 cells 
IL-17A is the hallmark cytokine for Th17 cells. Nevertheless, these cells also produce other 
cytokines, such as IL-21, IL-22, tumor necrosis factor (TNF)-ǂ, other members of the IL-17 
family and, specifically in humans, IL-26 (Dong 2008). As with Th1 and Th2 cells, no single 
surface marker is specific for Th17 cells. However, human Th17 cells are thought to 
preferentially express CD161 on the cell surface (Cosmi et al. 2008). Additionally, the 
selective expression of chemokine receptors in subsets of human memory T cells has been 
useful in defining lineages with different effector functions and migratory capacity (Sallusto, 
Mackay, and Lanzavecchia 2000). It has been shown that human Th17 cells express the 
chemokine receptor CCR6 and its ligand CCL20 (Dong 2008; Wilson et al. 2007). 
Coexpression of CCR4 and CCR6 further defines human T cells that produce IL-17 but not 
IFNǄ (Acosta-Rodriguez, Rivino et al. 2007). In contrast, expression of CCR6 and CXCR3 
identifies a more heterogeneous effector T cell population that produces both IFNǄ and IL-
17 (Acosta-Rodriguez, Rivino et al. 2007). These patterns of chemokine receptors appear to 
be biologically significant, as memory Th17 cells specific for Candida albicans are mainly 
CCR6+CCR4+ positive, whereas those that recognize Mycobacterium tuberculosis antigens are 
present in the CCR6+CXCR3+ subgroup producing both IFNǄ and IL-17 (Acosta-Rodriguez, 
Rivino et al. 2007; Annunziato et al. 2007).  
The combination of cytokines that stimulate differentiation of Th17 cells has been subject of 
much debate. Initial studies on human T cell differentiation indicated that T cell activation 
in the presence of IL-1ǃ, IL-6 and/or IL-23 was sufficient to induce Th17 cells, and that TGF-
ǃ inhibited this process (Acosta-Rodriguez, Napolitani et al. 2007; Chen et al. 2007; Crome, 
Wang, and Levings 2010; Wilson et al. 2007). In subsequent studies, however, TGF-ǃ was 
reported to be important for the development of human IL-17 producing cells (Manel, 
Unutmaz, and Littman 2008; Volpe et al. 2008; Yang, Anderson et al. 2008). This discrepancy 
could be explained by more recent reports showing that the requirement for TGF-ǃ in the 
differentiation process is indirect and relates to suppression of Th1 differentiation (Crome, 
Wang, and Levings 2010; Santarlasci et al. 2009). In the current view, the combination of IL-
1ǃ and IL-6 is essential for proper human Th17 cell differentiation whereas IL-23 is 
important for both expansion and survival of lineage-committed Th17 cells (Wilson et al. 
2007). In addition to cytokine-driven Th17 lineage commitment, it has also been shown that 
prostaglandin E2 (PGE2), which is a mediator of tissue inflammation, directly promotes 
differentiation, expansion and proinflammatory function of human and mouse Th17 cells 
(Yao et al. 2009). In humans, PGE2 induces up-regulation of the IL-23 and IL-1 receptors (IL-
23R and IL-1R, respectively) and by synergism with IL-1ǃ, IL-6 and IL-23 (Boniface et al. 
2009).  
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The observation that Th17 cells are a distinct lineage of cells with a unique cytokine and 
chemokine/chemokine receptor profile, led to the discovery of RORǄt in mice (Ivanov et al. 
2006). RORǄt encodes the retinoid orphan nuclear receptor, and this transcription factor is 
required for the differentiation of Th17 cells. In the human system it has also been shown 
that forced over-expression of RORC2 (the human equivalent of RORǄt) in human naïve T 
cells induces a Th17-like phenotype, by inducing IL-17A, IL-17F, IL-26 and CCR6 expression 
and down-regulating IFNǄ secretion (Manel, Unutmaz, and Littman 2008; Crome et al. 2009) 
(Figure 1). Activation of RORǄt also causes expression of the IL23R, indicating that IL-23 
acts on T cells that are already committed to the Th17 lineage. Exposure of developing Th17 
cells to IL-23 not only enhances the expression of IL-17 but also induces IL-22 and 
suppresses IL-10 and IFNǄ (McGeachy et al. 2007). Yet, RORC2 alone can induce IL-17 
production in only 20% of the T cell population (Chen and O'Shea 2008) indicating that it 
acts in cooperation with other transcription factors for full commitment of precursors to the 
Th17 lineage. In addition to RORC2, the most specific and master transcription factor, at 
least four other transcription factors are linked to the human Th17 cell fate. These include 
signal transducer and activator of transcription-3 (STAT3), interferon regulatory factor-4 
(IRF4), runt box transcription factor-1 (Runx1), and the aryl hydrocarbon receptor (AhR) 
(Chen and O'Shea 2008). Together they form a sophisticated network with positive and 
negative feedback loops. In addition, Th17 cells are inhibited by IL-2 (produced by Treg 
cells), IFNǄ (produced by Th1 cells), and IL-4 (produced by Th2 cells) but also by other 
negative regulators such as retinoic acid (Elias et al. 2008).  
Although this scheme of T helper cell differentiation might seem complex (Figure 1), it is in 
fact an oversimplification. Recent studies on T helper cell differentiation have revealed more 
plasticity in cytokine production than predicted by conventional models of T helper cell 
lineage commitment. Activated memory T cells preserve plasticity to alter their cytokine 
program according to the stimuli they receive. A cytokine restricted to one T helper subset 
can therefore be secreted by another subset under changing stimulation conditions. This 
feature is also observed in human Th17 cells (Chen and O'Shea 2008). Acquisition of IFNǄ-
producing potential by Th17 cells, particularly the simultaneous production of IFNǄ and IL-
17, is common (Chen et al. 2007; Wilson et al. 2007) (see Figure 2). Additionally, Th17 cells 
can even stop producing IL-17 and become selective IFNǄ producers resulting in a complete 
subset switch (O'Shea and Paul 2010). Although Th1 cells do not become IL-17 producers, 
under particular circumstances they can make IL-13 (Hayashi et al. 2007). Th17 cells produce 
IL-22, but cells that make IL-22 and not IL-17 (“Th22 cells”) have recently been identified as 
well (Duhen et al. 2009; Trifari et al. 2009). Simultaneous production of IL-22 and IFNǄ has 
also been described (O'Shea and Paul 2010). This plasticity even concerns master regulators: 
FoxP3 expression within Treg cells is heterogeneous and transient and former.  
Treg cells have the capacity to produce proinflammatory cytokines such as IL-17 (Bluestone 
et al. 2009). 
Moreover, also multiple master regulators can be expressed, such as Gata3 and FoxP3 in Tregs 
(Mantel et al. 2007), or a combination of RORC2 and FoxP3 (mixed Th17-Treg) (O'Shea and 
Paul 2010). Therefore, expression of master regulators should not be simplified as mutually 
exclusive but rather as a gradient of transcription factors (O'Shea and Paul 2010). It remains to 
be shown whether there are preferential directions for plasticity or whether effector T cells can 
change in any direction from every starting point (Bluestone et al. 2009). Plasticity could be an 
answer to the evolution of pathogens, allowing a proper response to new threats. 
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Fig. 2. Flow cytometric analysis of cytokine production by CD4+ T helper cells. 
With the use of a technique called flow cytometry, it is possible to depict the cytokine 
producing potential of individual cells. In this experiment peripheral blood mononuclear 
cell (PBMC) suspensions were stained with monoclonal antibodies specific for CD3, CD4, 
CD8, and the indicated cytokines. Live CD4+ CD3+ T cells were gated and analyzed for the 
presence of the indicated cytokines in combination with the CD45R0 marker for memory T 
cells. Results are shown as dot plots and illustrate that CD4+ T helper cells are capable of 
producing all of the tested cytokines (top row, right upper quadrants). Moreover, CD4+ T 
helper cells have the potential to be simultaneously positive for IL-17 and IFNǄ, and IL-17A 
and IL-22 respectively (bottom row, right upper quadrants). 
2.2 IL-17 producing cells other than Th17 cells 
Th17 cells are not the exclusive producers of IL-17 nor is this production their only function. 
Other cell populations capable of producing IL-17 include both adaptive and innate immune 
cells.  
Within the adaptive arm of the immune system, a subset of CD8+ cytotoxic T cells is also 
capable of producing IL-17. Studies have shown that these cells develop under conditions 
that are similar to those required by Th17 cells, but different from those required by IFNǄ 
producing CD8+ T cells (Kondo et al. 2009). However, adaptive immune responses cannot 
explain the early IL-17-mediated immune responses that have crucial roles during stress 
responses and host defense. Early responses are induced within hours following tissue 
injury or exposure to pathogens (Ferretti et al. 2003; Happel et al. 2003; Zheng et al. 2008), 
which is not enough time to allow for  Th17 differentiation, indicating that innate immune 
cells play a crucial role in these early responses. The key feature of this innate IL-17 response 
is the early neutrophil recruitment. This results in a more efficient resolution of infection, in 
the maintenance of mucosal barrier integrity, but also in the potential induction of 
autoimmunity (2). Recent studies have shown that Ǆǅ T cells are important innate-like IL-17-
producing cells during infectious diseases and autoimmune inflammation (Aujla, Dubin, 
and Kolls 2007; Sutton et al. 2009; Ito et al. 2009). Additionally, innate(-like) IL-17-producing 
cells described in literature include CD3+ invariant natural killer T (iNKT) cells, lymphoid 
tissue inducer (LTi)-like cells, natural killer (NK) cells and myeloid cells (Cella et al. 2009; 
Cua and Tato 2010; Michel et al. 2007).  
The Ǆǅ T cell subset is an innate-like immune cell population that has an important role at 
the mucosal barrier. These cells do not express the classical ǂǃ T cell receptor (TCR) but a Ǆǅ 
TCR instead. They bind to epitopes in much the same way as antibodies do and provide a 
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rapidly available source of IL-17 (Sutton et al. 2009). Like Ǆǅ T cells, iNKT cells play a 
pivotal role in immunity as they provide a rapid response, with the capacity to critically 
amplify and regulate adaptive immune responses (Godfrey et al. 2004). Initially, they have 
been divided into subsets that produce either IL-4 or IFNǄ, but recently a new IL-17-
producing subset that develops in the thymus has been described. This subset seems already 
committed to making IL-17 (Michel et al. 2008). The LTi cell represents a primitive precursor 
of NK, NKT, and CD4+ T cells. Specifically immature (CD127+) NK cells are closely related 
to LTi cells (Eberl et al. 2004). LTi cells promote the formation of lymphoid organs and 
sustain primed CD4+ T cell memory responses (Eberl et al. 2004). Thus, like IL-17 producing 
Ǆǅ T cells and NKT cells, LTi cells provide a rapidly available source of IL-17. Interestingly, 
it was recently recognized that innate lymphoid cells (ILCs) can be considered a family of 
non-T/non-B lymphocytes that includes not only NK and LTi cells, but also cells that 
produce IL-5, IL-13, IL-17 or IL-22. These ILC subsets are developmentally related and 
require cytokine signals through the common Ǆ-chain of the IL-2 receptor. The distinct ILC 
subsets, which seem to have important roles in protective immunity analogous to helper T 
cell subsets, were recently reviewed by Spits and DiSanto (Spits and Di Santo 2011). Next to 
LTi and NK cells, other innate IL-17 producers have been postulated, including 
macrophages and neutrophils (reviewed by (Cua and Tato 2010; Song et al. 2008), however 
data is limited and further studies are needed to understand more of their role in mucosal 
tissue.  
2.3 Interactions between Th17 and other cells of the immune system  
Cells of the immune system modulate each other’s function. Many cells may interact with 
Th17 cells including APCs, other T helper subsets, B cells and neutrophils (Figure 3). APCs 
play a central role in directing immune responses by secreting cytokines that polarize CD4+ 
T cells into distinct lineages. Several studies support the hypothesis that changes in APC 
function probably precede inappropriate development and expansion of Th17 cells. For 
example, monocytes from inflamed joints of rheumatoid arthritis patients promote the 
development to Th17 cells but not Th1 or Th2 cells via a cell-contact-dependent mechanism 
(Evans et al. 2009). Furthermore, it was found that monocyte-derived DCs from patients 
with multiple sclerosis secrete elevated levels of IL-23 when compared to healthy controls 
(Vaknin-Dembinsky, Balashov, and Weiner 2006). Additionally, in psoriasis DCs secrete IL-
1ǃ, IL-23 and CCL20, promoting both the development of Th17 cells and their migration to 
the skin (Kryczek et al. 2008). However, the initial stimuli that polarize APCs to produce 
cytokines that promote Th17 cells are still unclear. 
It has long been known that Th1 and Th2 cells antagonize each other’s differentiation and 
function. Not surprisingly, IFNǄ produced by Th1 cells and IL-4 produced by Th2 cells 
inhibit Th17 development (Bettelli, Oukka, and Kuchroo 2007). For Treg cells and Th17 cells 
there appears to be an even closer developmental relationship because the differentiation of 
both of these cell types require transforming growth factor (TGF)ǃ (Veldhoen et al. 2006). 
Additionally, Th17 differentiation is inhibited by Treg cells, via the production of IL-2. Th17 
cells can also modulate B cell function as has been shown by their ability to promote 
antibody production (IgM, IgG and IgA but not IgE) (Acosta-Rodriguez, Napolitani et al. 
2007). 
There is growing evidence that T cells are involved in orchestrating sustained mobilization 
of neutrophils. In the lungs for instance, in a subpopulation of COPD patients there is an 
accumulation of CD4+ and CD8+ T cells, which is associated with the presence of neutrophils  
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Fig. 3. Th17 cells act on other immune cells and on cells of non-hematopoietic origin. 
Cytokines produced by Th17 cells have the ability to act on other cells. This allows for a 
crosstalk between immune and non-immune cells to provide protection and promote 
inflammation. 
(Turato et al. 2002). IL-17 seems to be an important mediator of linking activated T cells to 
accumulation of neutrophils, although solid data on T helper cells and neutrophils are lacking. 
In vitro work confirmed that IL-17 orchestrated neutrophilic influx by the production of 
CXCL8 (IL-8), CXCL1 (GRO-a), and granulocyte-macrophage colony stimulating factor (GM-
CSF) in airway epithelial cells, smooth muscle cells, endothelial cells, and fibroblasts (Murphy 
et al. 2008). So, the importance of Th17 cells in neutrophilic inflammation lies in the ability of 
IL-17 to induce granulopoiesis, neutrophil chemotaxis, and the anti-apoptotic properties of G-
CSF (Kolls and Linden 2004; Ouyang, Kolls, and Zheng 2008). Accordingly, administration of 
IL-17A to the lung induces robust neutrophil recruitment (Laan et al. 1999), although – by 
contrast - chronic IL-17A/F overexpression resulted in enhanced lymphocyte and macrophage 
but not neutrophil numbers (Park et al. 2005; Yang, Chang et al. 2008).  
3. IL-17 in lung diseases 
Although Th17 cells have only recently been recognized as a distinct lineage of CD4+ T cells, 
associations between IL-17 and human disease have been known for many years. 
Particularly disorders previously classified as typical Th1 disease, such as rheumatoid 
arthritis (Kotake et al. 1999), inflammatory bowel disease (Fujino et al. 2003), and psoriasis 
(Arican et al. 2005), are now considered to be primarily Th17-driven. For that reason 
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(chronic) lung conditions previously believed to be Th1 cell disorders deserve special 
attention as Th17 cells might contribute to their pathogenesis. Moreover, immunity 
mediated by Th17 cells seems particularly important at epithelial and mucosal surfaces, as 
indicated by the distinct pattern of expression of Th17 subset-associated chemokine and 
cytokine receptors (Aujla et al. 2008; Ouyang, Kolls, and Zheng 2008).  
Because Th17 cells and IL-17 play a role in regulating neutrophilic and macrophage 
inflammation in the lung, a potential role in many different lung diseases including asthma 
and chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pulmonary infectious 
diseases, sarcoidosis and other interstitial lung diseases and rejection after lung 
transplantation, seems legitimate. Asthmatics were shown to have elevated levels of IL-17A 
mRNA and protein levels in induced sputum and these levels were positively correlated with 
disease severity (Bullens et al. 2006; Molet et al. 2001; Al-Ramli et al. 2009). In COPD, recent 
studies showed increased expression of Th17 cytokines in bronchial mucosa and sputum (Di 
Stefano et al. 2009; Doe et al. 2010). Airway neutrophilia is a major feature of CF exacerbations 
and it is shown that sputum IL-17 is upregulated and correlates with Pseudomonas aeruginosa 
colonization (Dubin and Kolls 2007). In infection models in mice, there is considerable 
evidence that IL-17 and/or IL-23 are important in host responses against Klebsiella pneumoniae 
(Tesmer et al. 2008). Furthermore, several studies have now linked IL-17 to fibrosis in the lung 
in mouse models of pulmonary fibrosis and idiopathic pulmonary fibrosis in humans (Braun 
et al. 2010; Kurasawa et al. 2000; Wilson et al. 2010). Similarly, Th17 cells and IL-17 may be 
important regulators of the airway fibrotic response driving the development of bronchiolitis 
obliterans syndrome (BOS) upon lung transplantation.  
For functional analysis of IL-17 producing cells in relation to other immune cells or 
epithelial cells, it is important to consider their anatomical localization. Obviously, 
bronchoscopy-guided or surgically guided biopsies allow histopathologically examination 
in situ, but are not frequently performed because they are invasive techniques. 
Bronchoalveolar lavage (BAL) is again not commonly performed except in lung 
transplantation and interstitial lung disease. For this reason sputum and nasopharyngeal 
washes are often studied. Blood and serum might be ideal to study because they are easily 
accessible. However, it is not always clear to what extend these compartments reflect what is 
happening in the lung. The methodology to study IL-17+ T cells in biopsies or in serum and 
BAL represents only indirect evidence of Th17 cells. Flow cytometry does provide direct 
evidence as it can combine several parameters (Figure 2). In this way, identification of 
distinct IL17+ T cells and even separate subpopulations is relatively simple. 
3.1 COPD and asthma 
COPD and asthma represent two classes of chronic obstructive lung disorders that may 
share some similar immunological disease mechanisms. COPD is marked by a progressive 
and irreversible airway obstruction and emphysematic changes in the lung. In asthma the 
airway obstruction is reversible and there is a marked airway hyperresponsiveness and 
airway inflammation. Recent studies on the immunological mechanisms of COPD and 
asthma pathogenesis point towards a role for IL-17 and Th17 cells in both diseases. 
3.1.1 COPD 
In COPD, chronic inhalation of toxic particles and gases causes destruction of lung 
parenchyma, activates epithelial cells, increases mucus production and stimulates migration 
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of many inflammatory cells (Hogg 2004; Hogg et al. 2004). This results in an abnormal 
inflammatory response in the small airways and alveoli. It is believed that both the innate 
and the adaptive immune system are involved in this inflammatory process (Barnes 2008; 
Hogg et al. 2004). Progression of the disease is associated with the presence of lymphoid 
follicles, a histological hallmark of an adaptive immune response and termed bronchus-
associated lymphoid tissue (BALT) collections. The presence of neutrophils, BALT 
collections, autoantibodies in the lungs, and also autoreactive T cells in the periphery, 
indicate CD4+ T cell involvement in the pathogenesis of COPD (Curtis, Freeman, and Hogg 
2007; Feghali-Bostwick et al. 2008; Hogg et al. 2004; Vanaudenaerde et al. 2011). A potential 
role for adaptive immune responses in COPD has also been suggested in studies that show 
expansion of lung T and B cells with oligoclonality in patients with COPD and in murine 
emphysema models (Motz et al. 2010; Sullivan et al. 2005). To date, there are only few 
studies examining the expression of IL-17A and IL-17F in COPD. However, since 
neutrophilic inflammation (including elevated CXCL8 levels) is a common feature of COPD 
(Barnes 2000), and infiltrating CD4+ T cells in COPD were previously considered to be Th1 
cells, it is expected that Th17 cells play an important role in this disease. 
Although direct evidence for the role of IL-17 and Th17 cells in COPD remains largely 
absent, the importance of IL-17 in stimulating chemokine production and the role of 
neutrophils and macrophages in promoting COPD pathogenesis have led to interest in a 
potential connection (Curtis, Freeman, and Hogg 2007). Another possible link derives from 
the ability of IL-17 to drive matrix metalloproteinases (MMP)9 production, a protein which 
is involved in the breakdown of extracellular matrix, as is observed in emphysema (Prause 
et al. 2004). It is also known that IL-17-mediated signalling induces target cells to produce 
various inflammatory mediators such as TNF-ǂ, IL-6 and IL-1ǃ. Interestingly, increased 
levels of IL-6 and TNFǂ are found in sputum and BAL fluid and have been associated with 
disease severity in patients with COPD (Hacievliyagil et al. 2006). TNFǂ promotes CXCL8 
expression from airway epithelial cells. Elevated levels of serum TNFǂ have also been 
linked to exacerbations in COPD patients (Calikoglu et al. 2004). In addition TNFǂ 
production by mast cells is increased due to IL-17A, leading to neutrophil infiltration in the 
airways (Feldmann et al. 2001). Furthermore, IL-17 is capable of increasing mucin 
production from airway epithelial cells (Prause et al. 2004) and excessive mucus production 
is one of the characteristic of COPD. Recently it was shown that patients with stable COPD 
exhibited elevated numbers of IL-22- and IL-23-positive cells in the bronchial epithelium 
and IL-17-positive cells in the submucosa when compared to healthy controls (Di Stefano et 
al. 2009; Doe et al. 2010; Chang et al. 2011). Additionally, airway smooth muscle cells from 
COPD patients express IL-17RA and respond to IL-17 by inducing CXCL8 production 
(Rahman et al. 2005). In contrast to these findings, the levels of IL-17 in sputum from 
patients with COPD do not differ from control subjects (Barczyk, Pierzchala, and Sozanska 
2003). In addition to human studies, mice exposed to cigarette smoke exhibit enhanced IL-17 
production (Melgert et al. 2007; Harrison et al. 2008). Experiments on murine lung epithelial 
cells have also shown that overexpression of IL-17A induces a COPD-like lung 
inflammation (Park et al. 2005). Taken together, these findings indicate a role for Th17 cells 
in COPD, but it is still unclear whether and how these cells contribute to disease 
pathogenesis or progression. Moreover, to what extend Th1 and Th17-mediated immune 
responses affect airway obstruction, emphysematic changes, inflammation or COPD 
exacerbations are questions that need to be addressed.   
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3.1.2 Asthma 
Asthma is usually characterized by concurrent airway inflammation, cytokine production, 
and airway hyperresponsiveness to relevant antigens and a specific trigger. The central role 
of the Th2 subset in the disease, inducing airway eosinophilia and bronchial 
hyperresponsiveness, is well accepted. Individually, the Th2 cytokines can explain many of 
the salient features of asthma, including IgE induction in B cells (IL-4), airway eosinophilia 
(IL-5) goblet cell hyperplasia (IL-4, IL-13) and bronchial hyperreactivity (IL-13 acting on 
bronchial smooth muscle cells) (Wills-Karp et al. 1998). However, some individuals with 
asthma display airway neutrophilia rather than eosinophilia (Anderson 2008). It appears 
that in those patients with asthma in which inflammation is nonatopic, non-IgE-dependent, 
and noneosinophilic, airway neutrophilia is correlated with asthma severity. This suggests a 
major role for neutrophils, at least in this subset of patients with asthma (Louis et al. 2000). 
Neutrophilic inflammation has also been described in sudden-onset fatal asthma and 
neutrophil numbers are highly elevated in status asthmaticus (Lamblin et al. 1998). These 
observations suggest a role for these cells in severe and fatal asthma (Cosmi et al. 2011). 
With the involvement of neutrophils, several studies tried to find an association between 
Th17 lymphocytes and asthma. 
Asthmatics have elevated levels of IL-17A mRNA and protein in breath condensate, 
sputum, BAL, and airway biopsies (Bullens et al. 2006; Pene et al. 2008; Molet et al. 2001).  
Furthermore, increased IL-17A and IL-17F levels are positively correlated to disease 
severity, suggesting an important role for IL-17A and IL-17F in severe asthma (Al-Ramli et 
al. 2009). Indeed, elevated IL-17A levels also correlate to increased neutrophilic 
inflammation, a characteristic of severe and steroid-resistant asthma (Bullens et al. 2006). 
One could also hypothesize that IL-17 may have opposite pathophysiological roles in 
different disease stages, as would be supported by findings in an asthma mouse model, 
indicating that IL-17A is required for induction of disease but negatively regulates 
established asthma (Schnyder-Candrian et al. 2006). IL-17F may also play an important role 
in the development of asthma, as a polymorphism in IL-17F which results in a loss-of-
function mutation, is inversely related to asthma risk (Hizawa et al. 2006). In these studies 
however, the cellular source of IL-17 remained unknown, but recent studies attributed the 
production of IL-17 primarily to CD4+ T cells (Pene et al. 2008; Tesmer et al. 2008). A novel 
subset of Th2 memory cells that co-express the key Th2 and Th17 transcription factors, 
GATA3 and RORCT, respectively, and coproduce Th2 and Th17 cytokines was recently 
described (Wang et al. 2010).  Interestingly, the number of IL-17+ Th2 cells was significantly 
increased in peripheral blood of atopic asthma patients. Compared with classical Th17 or 
Th2 cells, these IL-17+ Th2 cells had an increased capacity to induce influx of inflammatory 
leukocytes, and therefore are thought to represent key pathogenic cells promoting 
exacerbation of allergic asthma. 
3.2 Pulmonary infections 
There is considerable evidence that IL-17 and other Th17 cytokines are important in 
pulmonary host responses to infection by a variety of different bacteria, fungi and protozoa, 
and viruses. Also in infection, the major function of IL-17 appears to be to promote 
chemokine and pro-inflammatory cytokine production and consequent recruitment and 
activation of neutrophils and macrophages. Additionally, Th17 cytokines can control the 
infection by induction of anti-microbial peptides during the early immune responses at 
mucosal sites. Upon stimulation with various microbial agents, activated DCs secrete 
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cytokines which determine the type of adaptive immunity that develops, i.e., whether the 
immune response is skewed toward Th1 or Th17 cells. Nevertheless, Th17 responses do not 
always seem to have a protective effect in mucosal infections. Current studies suggest that 
limited and correctly timed Th17 responses are protective, when appropriately balanced 
with concurrent Th1 immunity, but that uncontrolled Th17 cell activity could lead to a 
counterproductive level of organ inflammation (Tesmer et al. 2008). 
Human studies on the role of IL-17 and Th17 cells in pulmonary infections are limited. The 
best human “model’’ demonstrating the role of IL-17 and Th17 cells in clearing pulmonary 
infections is Job's syndrome or the hyper-IgE syndrome. This syndrome is caused by loss-of-
function mutations in STAT3, resulting in the inability of naïve T cells to differentiate into 
Th17 cells. These patients manifest chronic, recurrent and severe bacterial and fungal 
infections (Milner et al. 2008). Although other factors such as disturbed neutrophil 
chemotaxis are also involved in hyper-IgE syndrome (Hill et al. 1974), the Th17 cell 
deficiency is prominent. This therefore suggests an essential role for Th17 cells in the host 
immune system.   
3.2.1 Bacteria 
The host response to bacteria is largely triggered by Toll like receptor (TLR) ligands 
stimulating the production of inflammatory mediators, such as the pro-inflammatory 
cytokines IL-1ǃ, IL-6 and TNFǂ, and the recruitment of phagocytic cells to the lung (Akira, 
Uematsu, and Takeuchi 2006). Several components of the innate immune system have been 
identified as key mediators of bacterial clearance such as neutrophils and macrophages. The 
role of Th17 cells in bacterial pneumonia is less clear. However, HIV patients with depleted 
CD4+ T cells are more susceptible to bacterial infections in the lung (Wolff and O'Donnell 
2003), indicating a role for T cells in bacterial pneumonia.  
One of the best studied bacterial pathogens in pulmonary host defense is Klebsiella 
pneumoniae. Klebsiella pneumoniae is a virulent Gram-negative pathogen that can cause 
pneumonia. In mice infected with this organism, TLR4 activation in the lung leads to 
production of IL-23 by DCs, which then stimulates CD4+, CD8+ and even Ǆǅ T cells to 
release IL-17 (Happel et al. 2003). Interestingly, both IL17A and IL17F are induced in a dose-
dependent fashion (Aujla et al. 2008; Happel et al. 2005). Accordingly, the protective effects 
of IL-17 in host defense against bacterial pathogens were shown in studies that compared 
the susceptibility of IL-17R-deficient and control mice to K. pneumoniae infection (Ye et al. 
2001). After intranasal infection, IL-17R-deficient mice were more susceptible to lung 
infection with K.  pneumoniae (Happel et al. 2005; Ye et al. 2001). The increased bacteraemia 
and mortality observed in these mice were associated with delayed neutrophil recruitment 
and reduced expression levels of CXCL1, CXCL2, and G-CSF in the lung 12–24 hrs after 
infection. Related experiments demonstrated the essential role of IL-23 in triggering IL-17 
production during this infection. Also IL-23-deficient mice are highly susceptible to K. 
pneumoniae and do not upregulate IL-17 in response to infection, whereas IL-17 production 
readily occurs after infection in control mice (Happel et al. 2005). Furthermore, 
administration of recombinant IL-17 restores the early chemokine response, enhances local 
production of TNFǂ and IL-1ǃ, and reduces the bacterial burden in IL-23-deficient mice 
after K. pneumoniae infection (Happel et al. 2005; Ye et al. 2001). Together, these findings 
demonstrate that IL-17 produced in an IL-23-dependent fashion is essential for early 
recruitment of neutrophils and other inflammatory cells to provide immunity to K. 
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pneumoniae infection. In these studies it was also shown that in addition to IL-17 also IL-22 is 
measurable during infection. In contrast to gene deletion of IL-17, which results in a 
substantial reduction of CXCL1 and G-CSF in response to bacterial challenge, antibody 
neutralization of IL-22 causes an even more profound defect in mucosal immunity that leads 
to rapid dissemination of bacteria from the lung to the spleen (Aujla et al. 2008). The loss of 
mucosal immunity was not associated with defects in G-CSF or CXCL1 but with loss of 
barrier function and anti-microbial protein expressed in lung epithelium. Thus while IL-17 
production by Th17 cells is critically important in host defense against K. pneumoniae 
infection in the airway because of its role in neutrophil recruitment and activation, IL-22 acts 
by augmenting the barrier defense against pathogens by triggering the production of anti-
microbial peptides and enhancing healing of the epithelium should it be breached (Aujla et 
al. 2008). Importantly, not only Th17 responses are necessary for optimal protective 
immunity to K. pneumonia. Also IL-12-driven Th1 responses, resulting in efficient IFNǄ 
production, contribute to the optimal bacterial clearance in a mouse model of K. pneumonia 
(Happel et al. 2005).  
Following these initial studies with K. pneumoniae, the importance of IL-23 and IL-17 in host 
defense has been further established for a growing list of pathogens. Similar to K. 
pneumoniae, in mice infected with Mycoplasma pneumoniae, infiltration of the lungs by 
neutrophils is dependent on IL-23–induced upregulation of IL-17 (Wu et al. 2007). 
Additionally, accumulating evidence suggests that another Gram-negative extracellular 
respiratory pathogen, Bordetella pertussis which causes the whooping cough, may bias the 
host response towards the production of Th17 cytokines by preferentially inhibiting IL-12 
and inducing IL-23 (Fedele et al. 2008). The above-referenced studies clearly demonstrate a 
protective role for Th17 effector cytokines in host defense against primary challenges with 
specific extracellular Gram-negative pathogens. Th17 response may also play a role in 
controlling primary infection with intracellular pathogens such as Mycobacterium 
tuberculosis, although a much more limited one when compared with extracellular bacterial 
pathogens. It was shown that although Th17 cells are not critical to the primary response to 
M. tuberculosis, Th17 activation is clearly involved in response to vaccination against 
tuberculosis (Khader et al. 2007). In addition to this Th17-mediated vaccine-induced 
immunity to M. tuberculosis, Th17 cytokine responses have also been implicated in vaccine-
induced immunity against B. pertussis (Higgins et al. 2006) and Streptococcus pneumoniae 
(Malley et al. 2006). This indicates that the host Th17 effector cytokines have evolved as 
protective immune mechanisms against extracellular bacteria but are dispensable for 
primary protection against most intracellular pathogens that require a Th1 pathway for 
protection, such as in tuberculosis infection. 
Pseudomonas aeruginosa is another Gram-negative pathogen. Although not as virulent as K. 
pneumoniae, P. aeruginosa is a highly adaptable pathogen that causes both acute and chronic 
pulmonary infections. Chronic colonization and infection in the lung is associated with pre-
existing airway disease such as CF. CF is a disease characterized by the excessive production 
of aberrantly hydrated mucus in the airways, resulting from mutations in the ion channel 
cystic fibrosis transmembrane conductance regulator (CFTR). This increased mucus 
production, blocks normal ciliary function and thereby enhances recurrent pulmonary 
infections. During pulmonary exacerbation, CF patients exhibit airway neutrophilia and 
elevated levels of IL-23 and both IL-17A and IL-17F in bronchoalveolar lavage fluid and 
sputum (McAllister et al. 2005). Recently it was shown that CD4+ Th17 cells are prominently 
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featured in the airway walls of CF patients but that NKT cells and Ǆǅ T cells are also sources 
of IL-17 in patients with CF (Tan et al. 2011). In the latter study, IL-17+ cells were correlated 
with CF and non-CF bronchiectasis, but not with the presence of P. aeruginosa. It has been 
shown that clearance of P. aeruginosa is dependent on Th17 responses (Dubin and Kolls 
2007).  
3.2.2 Fungi, viruses and other opportunistic pathogens 
Several reports from mouse and human studies have shown that Th17 cells are important 
for clearing opportunistic infections such as Cryptococcus neoformans, Pneumocystis jirovecii 
and Candida albicans. E.g. patients with Job’s syndrome are extremely susceptible to 
mucocutaneous fungal infections caused by Candida species. It has been suggested that 
Th17 cytokines, particularly IL-17, contribute to tissue pathology in invasive Aspergillus 
infection in the lung particularly in the setting of NADPH oxidase deficiency (Romani et al. 
2008). In respiratory tract models of fungal infections using P. jirovecci, induction of IL-23 
and IL-17 following pathogen challenge is protective, since IL-23KO mice or neutralization 
of the IL-23/IL-17 axis resulted in impaired clearance of the pathogen (Rudner et al. 2007). 
Human viruses can induce IL-17 responses, as shown for herpes simplex virus (Maertzdorf, 
Osterhaus, and Verjans 2002) and respiratory syncytial virus (Hashimoto et al. 2005). 
Human rhinovirus infections are associated with exacerbations of asthma and COPD and 
IL-17 was shown to function synergistically with human rhinovirus to induce IL-8 from 
epithelial cells. This may contribute to the recruitment of neutrophils, immature DCs and 
memory T cells to the lung contributing to severe inflammatory profiles seen during viral 
exacerbations of airway disease (Wiehler and Proud 2007).  
Taken together, there is accumulating evidence for the involvement of IL-17 in bacterial, 
fungal and viral infection in the respiratory system in the mouse, whereas in human the role 
of IL-17 or Th17 cells is largely unexplored. 
3.3 Sarcoidosis, pulmonary fibrosis and other interstitial lung diseases  
Interstitial lung diseases (ILD) refer to a very heterogeneous group of lung diseases affecting 
the lung parenchyma. The exact nature of the initiating event and the subsequent cascade of 
mechanistic proceedings are most likely different in every single ILD. Multiple factors are 
likely to be involved but it is now clear that the immune system plays a major part in the 
pathogenesis of ILD. A similarity in every ILD is the interaction of growth factors, cytokines, 
and other mediators with cells that reside in the lung which seem to form part of the cascade 
of events that have been identified in the pathogenesis.  
Recent data point to a potential role of IL-17 and Th17 cells in a number of ILD. E.g. 
Wegener granulomatosis (Abdulahad et al. 2008), Langerhans histiocytosis (Coury et al. 
2008), and hypersensitivity pneumonitis (Joshi et al. 2009; Simonian et al. 2009) have been 
reported to be linked to IL-17. Pulmonary IL-17 producing Ǆǅ T cells have also been detected 
in response to bleomycin-induced tissue damage, a model for induced pulmonary fibrosis 
(Braun et al. 2010). Conversely, a particular subset of Ǆǅ T cells secreting IL-17 has been 
shown to contribute to hyperinflammatory granulomatous disease and fatal lung tissue 
damage during pulmonary aspergillosis (Romani et al. 2008). Recently, also sarcoidosis was 
suggested as a Th1/Th17 multisystem disorder (Facco et al. 2011), based on the presence of 
IL-17 positive CD4+ T cells in sarcoid lung tissue and their ability to respond to the 
chemotactic stimulus CCL20. Moreover IL-17A was expressed by macrophages infiltrating 
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sarcoid tissue. Sarcoidosis is a systemic inflammatory disease characterized by non-
caseating granulomas in various organs with pulmonary involvement in over 90% of 
patients (ATS 1999). These granulomas are compact, organized collections of macrophages 
and epithelioid cells, surrounded by and infiltrated with T lymphocytes, but the 
pathological processes that result in granulomatous inflammation are largely unknown. The 
accumulation in the lung of apparently oligoclonal IFN-producing T helper cells in 
sarcoidosis indicated an antigen-driven Th1 response (Rosen 2007; Zaba et al. 2010). Also 
because IL-17A has been implicated in the formation of a mycobacterial infection-induced 
granuloma in the lung (Curtis and Way 2009), we investigated Th17 cells by intracellular 
flow cytometry and immunohistochemistry in blood, BAL and bronchial mucosal biopsies 
from a cohort of newly diagnosed sarcoidosis patients and healthy controls. These studies 
provided evidence for the involvement of the Th17 lineage in sarcoidosis: IL-17A-expressing 
T cells were present in and around the granuloma and IL-22-expressing T cells were found 
in the subepithelial lamina propria in mucosal biopsies of sarcoidosis patients (Figure 4). 
This was accompanied by the presence of IL-17A+, IL-17A+IFN+ and IL-17A+IL-4+ memory 
T helper cells in BAL and by a significant increase in the proportions of these cells in the 
circulation (ten Berge et al. 2011).  
 
  
Fig. 4. IL-17A+ and IL-22+ cells in sarcoidosis lung biopsies containing granulomas. 
Hematoxylin nucleus staining and IL-17A (left) and IL-22 (right) staining of lung mucosal 
frozen sections from a granuloma-containing sarcoidosis biopsy (40 x magnifications). 
Arrows indicate IL-17A+ cells as well as diffuse IL-17A staining in red (left) and IL-22+ cells 
as well as diffuse IL-22 staining in the epithelium in red (right). 
3.4 IL-17 in transplantation 
Organ transplantation is currently a valid treatment option for selected patients with end-
stage disease. Graft rejection is still the most severe complication following organ 
transplantation. In lung transplantation, episodes of acute rejection (AR) tend to lead to 
chronic rejection, which is the main cause of late graft loss and poor long-term survival (Lee, 
Christie, and Keshavjee 2010; Burton et al. 2007). The diagnosis of AR is based on clinical 
findings and/or histological confirmation in transbronchial biopsies (Vanaudenaerde et al. 
2006). It has been shown that in addition to the frequency and severity of AR, also other risk 
factors such as ischemia-reperfusion injury (Lee, Christie, and Keshavjee 2010), gastro-
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oesophageal reflux (King et al. 2009), CMV pneumonitis and other infections (Valentine et 
al. 2009) are associated with an increased risk of chronic rejection. Chronic graft rejection, 
clinically known as BOS is defined as a progressive decline in lung function with other 
underlying conditions being absent (Estenne et al. 2002). More than 50% of the patients 
surviving five years after lung transplantation suffer from BOS (Christie et al. 2010). 
Classically, graft rejection has been shown to be mediated by CD4+ and CD8+ T cells (Heeger 
2003). Th1 cells were associated with graft rejection, whereas Th2 cells were considered to 
protect against rejection (Piccotti et al. 1997). Evidence is accumulating for an important role 
of IL-17 in allograft rejection, both in rodent models and humans. Prior to the first 
description of Th17 cells, IL-17 was implicated in the process of allograft rejection. Blocking 
IL-17 function in a rat cardiac allograft transplantation model increased graft survival 
significantly (Antonysamy et al. 1999). Around that same period, a number of reports 
highlighted the importance of IL-17 in the context of renal transplantation. Already in 1998 
it was shown that IL-17 was detectable by immunofluorescent staining of acutely rejecting 
human renal transplant biopsies, but not in healthy kidneys or pre-transplant biopsies (Van 
Kooten et al. 1998). Moreover, elevated IL-17 mRNA and protein levels could be detected in 
renal biopsy specimens and urinary sediment from patients found to have subclinical 
rejection when compared with control samples without any evidence of rejections (Loong et 
al. 2002). Additionally, elevated IL-17 mRNA and protein levels were detectable as early as 
the second post-operative day in a rat renal allograft model and its appearance is followed 
by the local production of pro-inflammatory molecules known to be induced by IL-17 
(Hsieh et al. 2001).  
It is important to keep in mind that transplantation procedures themselves may have a 
direct effect on the cytokine profile within the graft. Following an organ harvest the 
ischemia-reperfusion injury results in the release of a number of inflammatory mediators. 
These mediators include some of the cytokines that are important in T cell differentiation 
such as TGFǃ (Basile et al. 2001). A recent study demonstrated that factors released by 
human endothelial cells as a consequence of ischemia-reperfusion injury could enhance the 
production of both IL-17 and IFNǄ by CD4+ T cells (Rao, Tracey, and Pober 2007). These 
findings indicate that perioperative factors might result in increased Th17 activity within the 
graft. 
3.4.1 IL-17 in lung transplantation 
In lung transplantation, IL-17 has been implicated in ischemia reperfusion injury, acute 
rejection, infection and BOS (Bobadilla et al. 2008; Vanaudenaerde, De Vleeschauwer et al. 
2008; Yoshida et al. 2006). At day 28 after lung transplantation, IL-17 mRNA levels were 
found to be elevated in the bronchoalveolar lavage (BAL) fluid from patients with acute 
rejection when compared with those without rejection. This difference disappeared at longer 
follow up (Vanaudenaerde et al. 2006). These increased IL-17 levels were associated with 
increased numbers of both BAL lymphocytes and neutrophils and correlated with the 
severity of rejection (Vanaudenaerde et al. 2006). However, such a correlation with severity 
of rejection could not be confirmed in another study even though this study did show 
increased numbers of IL-17 positive cells in endobronchial biopsies early after lung 
transplantation (Snell et al. 2007). These apparently conflicting results may be explained by 
differences in the time of sampling, suggesting that early events after transplantation may 
be critical for inducing IL-17 production or that patient selection is crucial (Shilling and 
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Wilkes 2011). Additionally, patient heterogeneity may also cause conflicting results, e.g. by 
including both unilateral and bilateral transplant patients or by not discriminating between 
primary lung diseases.  
Protein levels of IL-6 and IL-1ǃ and mRNA levels for TGF-ǃ, IL-17, IL-23 and IL-8 in BAL 
fluid were increased in lung transplant recipients with BOS when compared to controls 
(Vanaudenaerde, Wuyts et al. 2008). CXCL8, a potent chemoattractant for neutrophils, has 
previously been associated with BOS, but it was unclear whether the presence of neutrophils 
was just a marker of general inflammation or a key mediator of obliterative bronchiolitis 
(McDyer 2007). Since IL-17 promotes neutrophil chemotaxis, the presence of neutrophils has 
been suggested to be secondary to a Th17-mediated alloimmune or autoimmune response 
(Shilling and Wilkes 2011). In a mouse model increased levels of IL-6 and IL-17 also 
correlated with tracheal obliteration, and blockade of IL-6 decreased both allograft fibrosis 
and IL-17 transcripts (Nakagiri et al. 2010). Increased neutrophilic inflammation of the 
airways with upregulation of IL-8 is common in the BAL of BOS patients. However, there 
are also many of these patients without considerable BAL neutrophilia despite the fact that 
they seem to be in an identical clinical condition with progressive decline in lung function, 
compatible with BOS. This may indicate the existence of different phenotypes within BOS 
with possible different treatment strategies. BAL neutrophilia might therefore be an 
important tool to select patients who might benefit from azithromycin treatment, since it has 
been demonstrated that azithromycin significantly reduces airway neutrophilia and CXCL8 
in patients with BOS (Gottlieb et al. 2008).  
Th17 cell responses may also trigger BOS by facilitating autoimmune responses, because 
autoantibodies against collagen type V have been described to be involved in lung allograft 
rejection (Burlingham et al. 2007). Immunohistochemical analysis indicated that collagen V 
becomes exposed in the lung matrix after ischemia-reperfusion injury in rat lung isografts 
and allografts (Yoshida et al. 2006), and that collagen V peptides are released in the BAL 
(Haque et al. 2002). Additionally, in humans it has been shown that pre-transplant patients 
who exhibit collagen V reactivity have an increased incidence of early graft dysfunction 
following lung transplantation (Bobadilla et al. 2008). 
Recent observations in our own group indicate that not only in BOS but also in stable lung 
transplantation patients IL-17 and other Th17 cytokines might play a role. We found 
enhanced Th17 differentiation of peripheral blood mononuclear cells (PBMC) in a group of 
stable lung transplantation patients, compared with both healthy individuals and patients 
on the waiting list for a lung transplantation. The increase in the proportions of circulating 
Th17 cells was not linked to donor-specific haploreactivity. Interestingly, increased 
proportions of circulating IL-17A+ CD4+ T cells co-expressing IFNǄ were found, indicating 
that specific Th17 subpopulations may have a functional role in stable lung transplantation 
patients (Paats et al., unpublished data). 
4. Therapeutic potential 
Accumulating evidence suggests that IL-17 and other cytokines involved in the Th17 
pathway play an important role in the pathogenesis of various lung diseases. Interference 
with the activity of Th17 cells or the inflammatory mediators that either induce them (IL-1ǃ, 
IL-6, and IL-23), act in concert with IL-17 (TNFǂ and IL-1ǃ), or work downstream of IL-17 
could be an effective treatment modality. One of these novel treatment modalities is cell 
blockade by monoclonal antibodies. Most antibody therapies have not yet been tested in 
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lung pathology, which is remarkable because of the lung’s continuous exposure to external 
triggers and pathogens. The risks of monoclonal antibody therapies must also be kept in 
mind. Adverse effects including infections, cancer and autoimmune disease are all issues 
that need consideration before antibody treatment can be introduced (Hansel et al. 2010). 
The most direct way to control the biologic effects of Th17 cells would be to target 
production of their effector cytokines. Monoclonal antibodies against IL-17 or the IL-17R 
and a soluble IL-17R have been developed for clinical application. Administration of 
LY2439821, an anti-IL-17 monoclonal antibody, has been described in RA and improved 
signs and symptoms of the disease, without significant adverse events (Genovese et al. 
2010). Additionally, it is promising that clinical trials with the fully human antibody, 
AIN457, in RA, psoriasis and noninfectious uveitis, show that targeting IL-17A interrupts 
inflammation and reduces disease activity (Hueber et al. 2010). Inhibitors of other products 
of Th17 cells such as IL-21 and IL-22 have not reached the clinical setting (Ma et al. 2008; 
Young et al. 2007). Another option might be to down-regulate IL-1ǃ, IL-6 and IL-23, the 
cytokines that induce Th17 differentiation. Targeting the IL-6R with a monoclonal antibody 
(e.g., tocilizumab, a humanized monoclonal antibody against the receptor) and neutralizing 
the IL-1R with an antagonist (e.g., anakinra, a recombinant human IL-1R antagonist) are two 
effective approaches to the treatment of rheumatoid arthritis and other autoimmune 
inflammatory diseases (Dinarello 2005; Yokota et al. 2005). A monoclonal antibody 
(ustekinumab) targeting the shared IL-12/IL-23 p40 subunit, blocks both Th1 and Th17 cells 
and was shown to be efficient in the treatment of psoriasis and Crohn’s disease (Griffiths et 
al. 2010). IL-17 induces the production of IL-1ǃ and TNFǂ. Antibodies, antagonists or 
receptor antagonists to IL-1 and TNFǂ are already in use for a range of autoimmune and 
chronic inflammatory conditions (Sutton et al. 2009). Unfortunately, recurrence of 
immunoinflammatory disease when treatment with TNFǂ inhibitors is discontinued is 
common. A combination of IL-17 and TNFǂ inhibitors, administered either simultaneously 
or sequentially, might be a good alternative to better control inflammation (Nadkarni, 
Mauri, and Ehrenstein 2007; Miossec, Korn, and Kuchroo 2009). Targeting intracellular 
signaling molecules or transcriptional factors involved in the activation of IL-17 production 
e. g. by small molecule inhibitors is an alternative approach for the development of new 
drugs. However, it is complicated by the fact that many of the signaling pathways are not 
unique to the IL-23-IL-17 axis and may also inhibit responses of other cell types involved in 
protective immunity (Mills 2008).  
Non-selective blockade of the adaptive immune system by the use of steroids or 
cyclosporine seem ineffective in patients with severe asthma, COPD and CF (Barnes 2008; 
Vanaudenaerde et al. 2011). This is probably due to the reported steroid resistance of the 
Th17 cell–neutrophil axis (McKinley et al. 2008). Other medication capable of dampening the 
innate immune system might be an alternative way to interfere with the Th17 pathway. The 
best documented therapy for reducing IL-17-T cell-mediated neutrophilia is macrolide 
therapy, which is being used effectively in clinical practice in patients with CF, asthma, 
COPD and BOS (Jaffe and Bush 2001; Seemungal et al. 2008). In addition, in vitro studies 
have shown that vitamin D inhibits Th17 cells (Mora, Iwata, and von Andrian 2008; Colin et 
al. 2010), hence vitamin D therapy might have potential in controlling Th17-mediated lung 
diseases. Clinical trials that could prove the importance of vitamin D in chronic lung 
diseases are currently in progress. Furthermore, other medication capable of interfering with 
the innate immune system, such as vitamin A or statins, merits attention (Vanaudenaerde et 
al. 2011). 
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5. Conclusions 
We still have much to learn about the phenotype, function and regulation of human Th17 
cells. It is however clear that IL-17 and other Th17 associated cytokines play a central role in 
regulating diverse immune responses. With their potential to induce a pronounced 
neutrophilic inflammation, which is a common feature of many pulmonary inflammatory 
conditions, Th17 cells are subject of great research interest. Important to realize is that 
besides Th17 cells there are also other sources of IL-17, including CD8+ T cells, Ǆǅ T cells, NK 
T cells, and LTi cells.  Depending on the timing, the tissue, and the local microenvironment, 
IL-17 secreting cells appear to be able to play both beneficial and detrimental roles in lung 
immunity and disease. The exact balance of these roles during the processes of many 
autoimmune and infectious diseases is however not fully understood yet. Therefore, the 
challenge lies in uncovering strategies to maximize the protective effect of IL-17 producing 
cells while simultaneously preventing these cells from causing immune-mediated host 
damage. At present, therapies that modulate the Th17 cell pathway are being tested in the 
clinic with promising results.  
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